NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now owns 81,993 shares of the company’s stock, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The shares were sold at an average price of $15.00, for a total transaction of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00.

NeuroPace Trading Down 6.8 %

Shares of NPCE stock opened at $12.56 on Friday. The stock’s 50-day moving average price is $12.66 and its 200-day moving average price is $9.60. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $17.10. The stock has a market capitalization of $374.89 million, a price-to-earnings ratio of -12.56 and a beta of 2.05. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

Institutional Trading of NeuroPace

A number of large investors have recently added to or reduced their stakes in NPCE. BNP Paribas Financial Markets bought a new position in shares of NeuroPace during the 4th quarter valued at approximately $29,000. Wells Fargo & Company MN lifted its position in NeuroPace by 54.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after buying an additional 6,181 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of NeuroPace in the 4th quarter worth about $103,000. Finally, Birchview Capital LP purchased a new stake in shares of NeuroPace during the 4th quarter valued at about $112,000. Institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NPCE. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. UBS Group started coverage on NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.